Novartis (NOVN) PT Set at CHF 90 by Goldman Sachs Group
Novartis (VTX:NOVN) received a CHF 90 target price from investment analysts at Goldman Sachs Group in a research note issued on Friday. The brokerage presently has a “neutral” rating on the stock. Goldman Sachs Group’s target price suggests a potential upside of 16.49% from the stock’s current price.
Several other research analysts have also weighed in on the company. Bank of America set a CHF 87 target price on Novartis and gave the stock a “sell” rating in a report on Wednesday, December 6th. JPMorgan Chase & Co. set a CHF 84 target price on Novartis and gave the stock a “neutral” rating in a report on Friday, December 29th. Deutsche Bank set a CHF 83.50 target price on Novartis and gave the stock a “neutral” rating in a report on Wednesday, November 8th. Morgan Stanley set a CHF 92 target price on Novartis and gave the stock a “buy” rating in a report on Friday, December 1st. Finally, Kepler Capital Markets set a CHF 87 target price on Novartis and gave the stock a “buy” rating in a report on Wednesday, January 24th. Two research analysts have rated the stock with a sell rating, seven have issued a hold rating and seven have issued a buy rating to the company. The company presently has a consensus rating of “Hold” and an average price target of CHF 88.88.
Novartis (VTX NOVN) opened at CHF 77.26 on Friday. The firm has a market capitalization of $201,600.00 and a PE ratio of 25.00. Novartis has a twelve month low of CHF 72.45 and a twelve month high of CHF 88.30.
WARNING: “Novartis (NOVN) PT Set at CHF 90 by Goldman Sachs Group” was posted by Daily Political and is the property of of Daily Political. If you are accessing this report on another publication, it was illegally stolen and republished in violation of United States & international copyright law. The correct version of this report can be accessed at https://www.dailypolitical.com/2018/03/03/novartis-novn-pt-set-at-chf-90-by-goldman-sachs-group.html.
Novan, Inc, a clinical-stage drug development company, focuses on the development and commercialization of nitric oxide-based therapies in dermatology. Its lead product candidate is SB204, a cosmetically elegant topical gel that targets multiple mechanisms of action for the treatment of acne vulgaris.
Receive News & Ratings for Novartis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novartis and related companies with MarketBeat.com's FREE daily email newsletter.